Natoli Engineering Company, Inc. reveals a new, affordable selection of tablet analysis equipment. From balances to laboratoryblenders, and everything in between, there is a variety of analytical equipment to suit a variety of needs.
Exco InTouch, the leading provider of patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has joined the Electronic Patient-Reported Outcome (ePRO) Consortium, a programme run by the Critical Path Institute (C-Path), which strives to enhance the quality of patient reported outcomes (PRO) in the evaluation of new pharmaceuticals.
Aptalis Pharmaceutical Technologies, formerly Eurand Pharmaceutical Technologies, today announced that the European Commission granted marketing authorization for a new pediatric indication of a new oral granule formulation of Gilead Sciences, Inc.'s Viread® (tenofovir disoproxil fumarate) for HIV-1 infected children aged 2 to less than 6 years, and for HIV-1 infected children above 6 years of age for whom a solid dosage form is not appropriate.
Aptalis Pharmaceutical Technologies, formerly Eurand, focused on developing differentiated oral products utilizing its pharmaceutical technologies, today announces its sponsorship of the American Association of Pharmaceutical Scientists (AAPS) Research Achievement Awards in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and its participation in the 2012 AAPS Annual Meeting and Exposition October 14 – 18, 2012 in Chicago, Illinois.
FDA approvals, revenue gain and organic business growth are just a few of the topics that John Fraher, President, Aptalis Pharma, addresses during an on-air interview with Fintan Walton, CEO, PharmaVentures and PharmaTelevision. The interview, conducted during BIO 2012 in Boston, reflects Fraher’s commentary regarding the integration of companies post Axcan Intermediate Holdings’ acquisition of Eurand N.V. in 2011.
Aptalis Pharmaceutical Technologies, a business unit of Aptalis Pharma that focuses on developing differentiated oral products utilizing its pharmaceutical technologies, today announces its co-sponsorship of Controlled Release Society’s Young Investigator Award and its participation in the 39th Annual Meeting & Exposition of the Controlled Release Society July 15 – 18, 2012 in Québec City, Canada.
Aptalis Pharmatech, Inc. (previously known as Eurand, Inc.) and Cephalon, Inc. a wholly-owned subsidiary of Teva Pharmaceuticals Industries Ltd, and Anesta AG prevailed in their appeal to the U.S. Court of Appeals for the Federal Circuit which reversed a lower court’s determination and held that two patents covering the AMRIX® muscle relaxant (Cyclobenzaprine Hydrochloride Extended-Release Capsules) are valid.
GVK Biosciences (GVK BIO) today announced that it is extending its Clinical Biomarker Database (GOBIOM) license to the Biomarker Qualification Group of the US Food and Drug Administration (USFDA).
CROMSOURCE, a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions today announced successful completion of a project to upgrade their data management system to the new Oracle Clinical Release 4.6.4 (replacing version 4.5.3.).
Gyros AB, a leader in utilization of microfluidic technologies to miniaturize and automate immunoassays, announced today that Bio Laboratories Pte Ltd has become sole distributor for the company's nanoliter-scale immunoassay platform in Singapore.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.